All the news Showing 10 of 102 articles from: Treatment for people living with HIV and HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low Liz Highleyman / 26 February 2016 An interferon- and ribavirin-free regimen of sofosbuvir/ledipasvir (Harvoni) taken for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent hepatitis C virus (HCV) infection if their HCV viral ... U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 People with HIV and HCV co-infection achieve high HCV cure rates with grazoprevir/elbasvir Liz Highleyman / 16 November 2015 A dual combination of Merck's grazoprevir and elbasvir taken for 12 or 16 weeks cured most HIV-positive people with genotype 1, 4 or 6 hepatitis C virus (HCV) co-infection and was generally safe ... Sofosbuvir/ledipasvir for 8 weeks cures most hard-to-treat hepatitis C patients in real-world study Liz Highleyman / 10 November 2015 Most people with hepatitis C virus (HCV) in the GECCO German hepatitis C cohort who were treated with sofosbuvir/ledipasvir (Harvoni) for 8 weeks in a real-world clinical setting achieved sustained virological response, even those ... Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co-infection Liz Highleyman / 09 November 2015 Hepatitis C treatment that leads to sustained virological response (SVR) – generally regarded as a cure – was associated with a reduced risk of liver-related death and improved overall survival in an analysis ... New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment Keith Alcorn / 07 October 2015 A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at ... Interferon-free hepatitis treatment is highly effective for people with HIV and HCV co-infection in three studies Liz Highleyman / 10 August 2015 Three different interferon-free regimens – sofosbuvir/ledipasvir, AbbVie's 3D regimen and grazoprevir/elbasvir – were well-tolerated and cured more than 90% of participants with HIV and HCV co-infection in three clinical trials, confirming that HIV-positive ... Liver fibrosis regression after hepatitis C treatment linked to reduced complications and death in people with HIV and HCV co-infection Liz Highleyman / 06 August 2015 People with HIV and HCV co-infection, with liver cirrhosis, who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from ... ← Prev1...34567...11Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive